CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

202895Orig1s000

CHEMISTRY REVIEW(S)

NDA 202-895

Prezista™
(darunavir)
Oral Suspension
100 mg per mL

Tibotec, Inc.

Mark R. Seggel
ONDQA
Division of New Drug Quality Assessment II
Branch V

Table of Contents

Table of Contents 2

Chemistry Review Data Sheet 3

The Executive Summary 6

I. Recommendations 6

A. Recommendation and Conclusion on Approvability 6

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable 6

II. Summary of Chemistry Assessments 6

A. Description of the Drug Product(s) and Drug Substance(s) 6

B. Description of How the Drug Product is Intended to be Used 8

C. Basis for Approvability or Not-Approval Recommendation 9

III. Administrative 10

A. Reviewer's Signature 10

B. Endorsement Block 10

C. CC Block 10

Chemistry Assessment 11

I. Review of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body of Data 11

S DRUG SUBSTANCE 11

P DRUG PRODUCT 11

P.5 Control of Drug Product 11

P.5.1 Specification 11

P.7 Container Closure System 12

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 15

A. Labeling & Package Insert 15

III. List Of Deficiencies To Be Communicated 20

Chemistry Review Data Sheet

1. NDA 202-895

2. REVIEW #: 2

3. REVIEW DATE: 28-SEP-2011

4. REVIEWER: Mark R. Seggel

5. PREVIOUS DOCUMENTS:

Previous Documents (eCTD)		Document Date
Original submission	(0000)	29-MAR-2011
Amendment (mfg. facilities)	(0003)	26-APR-2011
Amendment (response to info. request)	(0019)	29-JUL-2011
Amendment (response to info. request)	(0024)	18-AUG-2011
Amendment (response to info. request)	(0025)	19-AUG-2011

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed (eCTD)		Document Date
Amendment (labeling)	(0030)	08-SEP-2011
Amendment (CMC)	(0031)	09-SEP-2011
Amendment (alternative dosing pipette)	(0032)	09-SEP-2011
Amendment (labeling)	(0033)	09-SEP-2011
Amendment (labeling)	(0034)	12-SEP-2011
Amendment (alternative dosing pipette)	(0035)	14-SEP-2011
Amendment (labeling)	(0036)	21-SEP-2011
Amendment (syringe graphics)	(0037)	22-SEP-2011
Amendment (labeling)	(0040)	28-SEP-2011

7. NAME & ADDRESS OF APPLICANT:

Name:	Tibotec, Inc.
Address:	920 U.S. Highway 202, P.O. Box 300 Raritan, NJ 08869-0602
Representative(s):	Charles Zezza, PhD Director, Global Regulatory Affairs
Telephone:	908-707-3451

8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Prezista™
   b) Non-Proprietary Name (USAN): Darunavir
   c) Code Name/#: TMC114 (TMC114 ethanolate); R319064; JNJ-25875382; 54179
   d) CAS Registry Number: ethanolate: 635728-49-3; [redacted] (b) (4): 206361-99-1

e) Chem. Type/Submission Priority:
   i. Chem. Type: 3
   ii. Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: 505(b)

10. PHARMACOL. CATEGORY: Antiretroviral/Systemic/HIV/Protease inhibitor (7030220)

11. DOSAGE FORM: Suspension

12. STRENGTH/POTENCY: 100 mg per mL

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _X_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)
_____SPOTS product – Form Completed

__X__Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT

Chemical Names:
1. [(1*S*,2*R*)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)-propyl]-carbamic acid (3*R*,3a*S*,6a*R*)-hexahydrofuro[2,3-*b*]furan-3-yl ester
2. Carbamic acid, [(1*S*,2*R*)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3*R*,3a*S*,6a*R*)-hexahydrofuro[2,3-*b*]furan-3-yl ester

USAN/INN: Darunavir

Structural Formula:



Molecular Formula and Molecular Weight:

Darunavir	$C_{27}H_{37}N_3O_7S$	547.66	
Darunavir ethanolate	$C_{27}H_{37}N_3O_7S \cdot C_2H_6O$	593.73	(b) (4) by weight)

Note: The labeled strength, 100 mg/mL, is based on the weight of darunavir.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.